Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Teva
Citi
AstraZeneca
Colorcon
Queensland Health
Healthtrust
Cerilliant
UBS
Chinese Patent Office
Accenture

Generated: October 16, 2017

DrugPatentWatch Database Preview

Details for Patent: 6,756,393

« Back to Dashboard

Which drugs does patent 6,756,393 protect, and when does it expire?


Patent 6,756,393 protects NUPLAZID and is included in one NDA.

This patent has twenty-eight patent family members in twenty countries.

Summary for Patent: 6,756,393

Title: Azacyclic compounds
Abstract:Compounds and methods are provided for the treatment of disease conditions in which modification of serotonergic receptor activity has a beneficial effect. In the method, an effective amount of a compound is adminstered to a patient in need of such treatment.
Inventor(s): Andersson; Carl-Magnus A. (Glostrup, DK), Croston; Glenn (San Diego, CA), Hansen; Eva L. (Glostrup, DK), Uldam; Allan Kjaersgaard (Glostrup, DK)
Assignee: Acadia Pharmaceuticals, Inc. (San Diego, CA)
Application Number:10/409,782
Patent Claim Types:
see list of patent claims
Compound;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Acadia Pharms Inc
NUPLAZID
pimavanserin tartrate
TABLET;ORAL207318-001Apr 29, 2016RXYesYes► Subscribe► SubscribeYY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 6,756,393

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
2,017,165,273► Subscribe
9,296,694Azacyclic compounds► Subscribe
9,765,053Methods of treatment using selective 5-HT2A inverse agonists► Subscribe
6,815,458 Azacyclic compounds► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 6,756,393

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria348808► Subscribe
Australia2005202257► Subscribe
Australia4007201► Subscribe
Australia780006► Subscribe
Brazil0108977► Subscribe
BrazilPI0108977► Subscribe
Canada2397981► Subscribe
China101230034► Subscribe
China1443167► Subscribe
Cyprus1118651► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

UBS
Accenture
Cipla
Farmers Insurance
Medtronic
Mallinckrodt
Queensland Health
Dow
Federal Trade Commission
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot